| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 04/29/2026 | ±5.1% | +0.7% | over-priced |
| 02/10/2026 | ±2.8% | +0.9% | over-priced |
| 10/30/2025 | ±4.1% | -0.3% | over-priced |
| 08/04/2025 | ±2.3% | +1.8% | over-priced |
| 05/01/2025 | ±3.9% | -0.6% | over-priced |
| 02/14/2025 | ±3.3% | -1.8% | over-priced |
| 10/31/2024 | ±4.5% | -0.6% | over-priced |
| 07/29/2024 | ±3.3% | +1.1% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $7.15 | $19.1B | $1.6B |
| Q4 FY2025 | — | $19.5B | $1.9B |
| Q3 FY2025 | $6.96 | $19.2B | $1.6B |
| Q2 FY2025 | $6.83 | $18.6B | $1.7B |
HCA (HCA) reports imminently, with the next report estimated for 10/26/2026. Across the last 8 reports, options priced an average ±3.7% earnings move while the stock actually moved 1.0% on average — the market has systematically over-priced HCA's earnings risk. Fundamentals into the print: EPS up 10.9% year-over-year, revenue up 4.3%. QuantLogix's live 5-factor engine currently reads HCA as a buy at 79/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →